Crude Oil Edges Higher; Colgate-Palmolive Posts Upbeat Earnings
Portfolio Pulse from Lisa Levin
U.S. stocks traded higher with the Nasdaq Composite gaining around 250 points. Colgate-Palmolive Company reported better-than-expected Q2 earnings with a sales growth of 7.5% YoY to $4.82 billion. Business First Bancshares, Reata Pharmaceuticals, and Roku also reported upbeat quarterly results. However, Tonix Pharmaceuticals, Sleep Number Corporation, and Eos Energy Enterprises saw a drop in their shares.
July 28, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Business First Bancshares reported upbeat quarterly results.
The positive quarterly results could lead to a short-term increase in Business First Bancshares' stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Colgate-Palmolive reported better-than-expected Q2 earnings with a sales growth of 7.5% YoY.
The better-than-expected earnings report and positive outlook for FY23 could lead to a short-term increase in Colgate-Palmolive's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Reata Pharmaceuticals' shares got a boost after Biogen agreed to acquire the company.
The acquisition announcement by Biogen could lead to a short-term increase in Reata Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Roku reported better-than-expected Q2 results and issued strong Q3 guidance.
The positive Q2 results and strong Q3 guidance could lead to a short-term increase in Roku's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Eos Energy Enterprises' shares fell after the company said it expects Q2 revenue of $0.2 million.
The low Q2 revenue expectation could lead to a short-term decrease in Eos Energy Enterprises' stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Sleep Number Corporation's shares were down after the company reported mixed Q2 results.
The mixed Q2 results could lead to a short-term decrease in Sleep Number Corporation's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Tonix Pharmaceuticals' shares dropped after pricing public offering of 7 million common shares at $1 per share.
The pricing of the public offering could lead to a short-term decrease in Tonix Pharmaceuticals' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90